bltob, page-2

Over the last couple of years or more the management of the company has certainly thrown up a mixed bag of outcomes so I thought that I would jot down my thoughts.

Positives

1) Development of our own programs (not just licensing)
2) Closed some partnership deals
3) Funds spent on progress towards the clinic and not on peripheral issues (eg starting legal cases)
4) Renewed focus on technical and sales development (Graham, Suhy and Stubbings appointed)


Negatives

A) Lack of attention to detail
B) Shifting the goal posts
C) Communication with shareholders
D) Unable to stir investor interest
E) Lack of clarification of extent of IP
F) Failure to update Tacere information/website (http://www.insideview.com/directory/tacere-therapeutics-inc this recent update by the business directory Inside View still shows Tacere as having a revenue of $4M and employing 8 people. The Tacere website does nothing to improve or refute this information. If we did have $4M in revenue through a subsidiary I think our share price would be a little higher than it is now. What is the truth?)

At the moment it would seem that the negatives outweigh the positives so now is the time for management to pull a rabbit out of the hat, close a deal with some real revenue and lift the share price!!!